First D1-like receptor PET imaging of the rat and primate kidney: Implications for human disease monitoring

American Journal of Physiology - Renal Physiology

Volumn 307, Issue 1, 2014, Pages

  Granda, Michael L ^a,b   Schroeder, Frederick A ^a   Borra, Ronald H J ^a   Schauer, Nathan ^a   Aisaborhale, Ehimen ^a   Guimaraes, Alexander R ^a   Hooker, Jacob M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Dopamine; Hypertension; Positron emission tomography; Renal dopamine; Renal PET

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE C 11; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANGIOTENSIN II; CARBON 11; DOPAMINE; DOPAMINE 1 RECEPTOR; LOSARTAN; RADIOLIGAND; UNCLASSIFIED DRUG; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; BENZAZEPINE DERIVATIVE; BENZOFURAN DERIVATIVE; DOPAMINE RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BINDING AFFINITY; CENTRAL NERVOUS SYSTEM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CORTEX; MALE; NONHUMAN; PAPIO ANUBIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; DISEASE MODEL; DRUG EFFECT; HYPERTENSION; KIDNEY; METABOLISM; RADIOASSAY; RENAL DOPAMINE; RENAL PET; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT;

DOPAMINE; HYPERTENSION; POSITRON EMISSION TOMOGRAPHY; RENAL DOPAMINE; RENAL PET;

ANIMALS; BENZAZEPINES; BENZOFURANS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE ANTAGONISTS; KIDNEY; PAPIO ANUBIS; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RENIN-ANGIOTENSIN SYSTEM;

EID: 84903604542     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00111.2014     Document Type: Article

References (26)

1. Abrams AC. Clinical Drug Therapy: Rationales for Nursing Practice (8th ed.). Philadelphia: Lippincott Williams & Wilkins, 2007.
2. Albrecht FE, Drago J, Felder RA, Printz MP, Eisner GM, Robillard JE, Sibley DR, Westphal HJ, Jose PA. Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest 97: 2283-2288, 1996.
3. Aperia AC. Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Annu Rev Physiol 62: 621-647, 2000.
4. Armando I, Villar VAM, Jose PA. Dopamine and renal function and blood pressure regulation. Compr Physiol 1: 1075-1117, 2011.
5. Bourne JA. SCH 23390: the first selective dopamine D1-like receptor antagonist. CNS Drug Rev 7: 399-414, 2001.
6. CDC. National Chronic Kidney Disease Fact Sheet 2010-Factsheets-Publication-Diabetes D.D.T. http://www.cdc.gov/diabetes/pubs/factsheets/ kidney.htm [19 Jul. 2013].
7. Cropley VL, Fujita M, Musachio JL, Hong J, Ghose S, Sangare J, Nathan PJ, Pike VW, Innis RB. Whole-body biodistribution and estimation of radiation-absorbed doses of the dopamine D1 receptor radioligand 11C-NNC 112 in humans. J Nucl Med 47: 100-104, 2006.
8. Dougherty DD, Kong J, Webb M, Bonab AA, Fischman AJ, Gollub RL. A combined [11C]diprenorphine PET study and fMRI study of acupuncture analgesia. Behav Brain Res 193: 63-68, 2008.
9. Granda ML, Carlin SM, Moseley CK, Neelamegam R, Mandeville JB, Hooker JM. Synthesis and evaluation of methylated arylazepine compounds for PET imaging of 5-HT(2c) receptors. ACS Chem Neurosci 4: 261-265, 2013.
10. Halldin C, Foged C, Chou YH, Karlsson P, Swahn CG, Sandell J, Sedvall G, Farde L. Carbon-11-NNC 112: a radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med 39: 2061-2068, 1998.
11. Harris RC. Abnormalities in renal dopamine signaling and hypertension: the role of GRK4. Curr Opin Nephrol Hypertens 21: 61-65, 2012.
12. Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension 32: 187-197, 1998.
13. Hussain T, Lokhandwala MF. Renal dopamine receptors and hypertension. Exp Biol Med (Maywood) 228: 134-142, 2003.
14. Johnson W, Nguyen ML, Patel R. Hypertension crisis in the emergency department. Cardiol Clin 30: 533-543, 2012.
15. Jose PA, Eisner GM, Drago J, Carey RM, Felder RA. Dopamine receptor signaling defects in spontaneous hypertension. Am J Hypertens 9: 400-405, 1996.
16. Kim CS. Pharmacologic management of the cardio-renal syndrome. Electrolytes Blood Press 11: 17-23, 2013.
17. Kochhar R, Brown RK, Wong CO, Dunnick NR, Frey KA, Manoharan P. Role of FDG PET/CT in imaging of renal lesions. J Med Imaging Radiat Oncol 54: 347-357, 2010.
18. Li D, Scott L, Crambert S, Zelenin S, Eklof AC, Di Ciano L, Ibarra F, Aperia A. Binding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activation. J Am Soc Nephrol 23: 421-428, 2012.
19. Li LP, Halter S, Prasad PV. BOLD MRI of the kidneys. Magn Reson Imaging Clin N Am 16: 613-viii, 2008.
20. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, Simone GD, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J. Heart Disease and Stroke Statistics-2010 Update A Report From the American Heart Association. Circulation 121: e46-e215, 2010.
21. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747, 1990.
22. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 30: 1741-1750, 2005.
23. Oparil S, Aronson S, Deeb GM, Epstein M, Levy JH, Luther RR, Prielipp R, Taylor A. Fenoldopam: a new parenteral antihypertensive Consensus roundtable on the management of perioperative hypertension and hypertensive crises. Am J Hypertens 12: 653-664, 1999.
24. Prasad PV. Functional MRI of the kidney: tools for translational studies of pathophysiology of renal disease. Am J Physiol Renal Physiol 290: F958-F974, 2006.
25. Smithburger PL, Kane-Gill SL, Nestor BL, Seybert AL. Recent advances in the treatment of hypertensive emergencies. Crit Care Nurse 30: 24-30, 2010.
26. Weiner DE. Public health consequences of chronic kidney disease. Clin Pharmacol Ther 86: 566-569, 2009.